[The effect of thyrostatic treatment on circulating thyrotropin-receptor antibodies in Basedow's disease].
In 80 patients with Basedow's disease (20 nontreated and 60 under treatment with methimazole) were examined. The antibodies inhibiting the binding of TSH (TBII) by the radioreceptor method (Thyrotropin-Receptor-Anti-Körper Assay = TRAK), TRH-test, T3, T4, FT4, FT. TRAK-positive) values above 15 u/l) were 80% of the nontreated and 20% of the treated patients. In the course of 3 up to 6 months from the start of the treatment 60% of the examined patients were negative and at the end of the 18th month--92% were negative. A significant difference in the frequency of the recurrences was found between the TRAK-positive and the TRAK-negative patients. Between the TRAK, FT3, FT4, the size of the struma, the presence of ophthalmopathy [correction of ophthalmycthere] are positive relations. The following conclusions are made: 1. The determination of TBII and TRAK is not only of diagnostic but also of prognostic importance. 2. Methimazole exerts a specific immunosuppressive action and can lead to an immunologic remission in a comparatively short time.
Lozanov
B
B
Kirilov
G
G
Ivanova
R
R
Khubaveshki
S
S
D000328:Adult; D000906:Antibodies / Q000097:blood*; D013956:Antithyroid Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood*; D005260:Female; D006111:Graves Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating; D008297:Male; D008713:Methimazole / Q000008:administration & dosage; D008875:Middle Aged; D011869:Radioligand Assay / Q000295:instrumentation / Q000379:methods; D011989:Receptors, Thyrotropin / Q000187:drug effects / Q000276:immunology*; D013997:Time Factors
D000906:Antibodies; D013956:Antithyroid Agents; D001323:Autoantibodies; D018828:Immunoglobulins, Thyroid-Stimulating; D011989:Receptors, Thyrotropin; D008713:Methimazole
Vliianie na tireostatichnoto lechenie vŭrkhu tsirkulirashtite tireotropinretseptorni antitela pri bazedova bolest.